Expertise in
7
conditions

Dr. Steven E. Kempers

Dermatology
Associated Skin Care Specialists, PA
11107 Ulysses St Ne, Suite 200, 
Blaine, MN 
Accepting New Patients
Expertise in
7
conditions
Associated Skin Care Specialists, PA
11107 Ulysses St Ne, Suite 200, 
Blaine, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Steven Kempers is a Dermatologist in Blaine, Minnesota. Dr. Kempers is highly rated in 7 conditions, according to our data. His top areas of expertise are Lamellar Ichthyosis, Nonbullous Congenital Ichthyosiform Erythroderma, Fetal Retinoid Syndrome, and Actinic Keratosis. Dr. Kempers is currently accepting new patients.

His clinical research consists of co-authoring 29 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Licenses
Specialist in MN
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Metropolitan Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

ASSOCIATED SKIN CARE SPECIALISTS, PA
11107 Ulysses St Ne, Suite 200, Blaine, MN 55434

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects with Moderate to Severe Chronic Allergic Contact Dermatitis
A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects with Moderate to Severe Chronic Allergic Contact Dermatitis
Enrollment Status: Completed
Publish Date: November 14, 2024
Intervention Type: Drug
Study Drug: EB01 Cream
Study Phase: Phase 2
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
Enrollment Status: Completed
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drug: QTORIN rapamycin anhydrous gel
Study Phase: Phase 3
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Drug
Study Drug: NFX-179
Study Phase: Phase 2
An Evaluation of the Safety and Effectiveness of the N-SWEAT Patch for the Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating
An Evaluation of the Safety and Effectiveness of the N-SWEAT Patch for the Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating
Enrollment Status: Completed
Publish Date: September 07, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
Enrollment Status: Completed
Publish Date: May 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
Enrollment Status: Completed
Publish Date: August 09, 2022
Intervention Type: Drug
Study Drug: NFX-179
Study Phase: Phase 2
A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
Enrollment Status: Terminated
Publish Date: November 18, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Enrollment Status: Completed
Publish Date: June 04, 2019
Intervention Type: Other, Biological
Study Phase: Phase 2
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
Enrollment Status: Withdrawn
Publish Date: November 07, 2017
Intervention Type: Drug, Device
Study Phase: Phase 3
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of LIPO-202 (Salmeterol Xinafoate for Injection) for the Reduction of Submental Subcutaneous Fat
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of LIPO-202 (Salmeterol Xinafoate for Injection) for the Reduction of Submental Subcutaneous Fat
Enrollment Status: Completed
Publish Date: October 20, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 12 Less Clinical Trials

29 Total Publications

Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1.
Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1.
Journal: Science advances
Published: May 01, 2024
Similar Doctors
Expertise in
12
conditions
Dr. Maria K. Hordinsky
Dermatology
Expertise in
12
conditions
Dr. Maria K. Hordinsky
Dermatology

Fairview Express Care

500 Harvard St Se, 
Minneapolis, MN 
 (13.3 miles away)
612-273-6000
Languages Spoken:
English, Ukrainian
See accepted insurances
Accepting New Patients
Offers Telehealth

Maria Hordinsky is a Dermatologist in Minneapolis, Minnesota. Dr. Hordinsky is highly rated in 12 conditions, according to our data. Her top areas of expertise are Autosomal Recessive Hypotrichosis, Alopecia Areata, Graham-Little-Piccardi-Lassueur Syndrome, and Alopecia Universalis. Dr. Hordinsky is currently accepting new patients.

Expertise in
52
conditions
Dr. Sara A. Hylwa
Dermatology
Expertise in
52
conditions
Dr. Sara A. Hylwa
Dermatology

Park Nicollet Clinic

5320 Hyland Greens Dr, 
Bloomington, MN 
 (23.9 miles away)
952-993-2400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sara Hylwa is a Dermatologist in Bloomington, Minnesota. Dr. Hylwa is highly rated in 52 conditions, according to our data. Her top areas of expertise are Contact Dermatitis, Erythema Multiforme, Stevens-Johnson Syndrome, and Comedones. Dr. Hylwa is currently accepting new patients.

Expertise in
5
conditions
Dr. Noah I. Goldfarb
Dermatology
Expertise in
5
conditions
Dr. Noah I. Goldfarb
Dermatology

Fairview Express Care

717 Delaware St Se, Suite 340, 
Minneapolis, MN 
 (13.2 miles away)
612-672-7422
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Noah Goldfarb is a Dermatologist in Minneapolis, Minnesota. Dr. Goldfarb has been practicing medicine for over 16 years is highly rated in 5 conditions, according to our data. His top areas of expertise are Hidradenitis Suppurativa, Basal Cell Skin Cancer, Dissecting Cellulitis of the Scalp, and Hypocomplementemic Urticarial Vasculitis. Dr. Goldfarb is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kempers's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile